NCT00938301View on ClinicalTrials.gov

A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Bipolar Depression
Interventions
DRUG

PF-04455242

Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.

DRUG

Placebo

PIC matching in appearance to PF-04455242 will be used to administer placebo.

Trial Locations (1)

06511-5473

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00938301 - A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter